指南与共识重症综合管理与镇静镇痛

人工智能、健康与当今及未来的医疗:JAMA人工智能峰会报告

AI, Health, and Health Care Today and Tomorrow: The JAMA Summit Report on Artificial Intelligence.
PubMed 文献 · JAMA · 2025-01-01
一句话结论JAMA峰会报告指出:AI已广泛用于医疗但健康效果常未被量化,需在四个领域建立能快速、稳健、可推广评估其健康后果的生态系统。

该报告基于JAMA人工智能峰会讨论,指出AI正在以空前规模改变健康与医疗,潜在获益巨大但风险同样巨大。AI工具涵盖临床工具(如脓毒症警报、糖尿病视网膜病变筛查软件)、个人健康应用、医疗系统运营工具及混合工具,许多已广泛用于医学影像、移动健康、运营和门诊记录。这些工具的健康效应常未被量化,因为评估极困难或未被要求,部分因不受美国食品药品监督管理局监管。报告提出四个优先领域:全产品生命周期多利益相关方参与、开发推广评估与监测的测量工具、建立全国代表性数据基础设施与学习环境、建立激励结构。

要点

  • AI工具的健康效应常未被量化,因评估极困难或未被要求,部分因不受美国食品药品监督管理局监管。
  • 评估的主要挑战是工具效果高度依赖人机界面、用户培训和工具使用场景。
  • 多数负责任使用AI的标准聚焦安全监测(如模型幻觉检测)或机构流程合规,未涉及有效性(即改善结局的证明)。
  • 确保AI公平部署并改善健康结局或安全提升效率,需在四个领域取得进展:多利益相关方全生命周期参与、评估监测测量工具、全国代表性数据基础设施、激励结构。
  • AI将扰动医疗各环节,但改善全民健康的可能性取决于能否建立快速、高效、稳健、可推广地获取AI健康后果知识的生态系统。

研究设计与关键结果

  • JAMA人工智能峰会报告讨论了健康与医疗AI应如何开发、评估、监管、推广和监测。
  • AI工具包括临床工具(如脓毒症警报或糖尿病视网膜病变筛查软件)、个人健康应用、医疗系统运营工具(如收入周期管理或排班)及混合工具(如记录和计费、建议诊断或治疗方案)。
  • 许多AI工具已被广泛采用,尤其在医学影像、移动健康、医疗业务运营和门诊记录等混合功能方面。
  • 确保AI公平部署并改善健康结局或安全提升效率,需在四个领域取得进展:全产品生命周期多利益相关方参与、开发推广评估与监测测量工具、建立全国代表性数据基础设施与学习环境、建立激励结构。

证据类型、等级与局限

  • 证据类型:JAMA峰会报告(专家意见)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,AI将扰动医疗各环节,但改善全民健康的可能性取决于能否建立快速、高效、稳健、可推广地获取AI健康后果知识的生态系统。
  • 作者认为,确保AI公平部署并改善健康结局或安全提升效率,需在四个领域取得进展:多利益相关方全生命周期参与、评估监测测量工具、全国代表性数据基础设施、激励结构。
  • 原文未据此给出推荐。

指南或共识出处

  • JAMA人工智能峰会报告(JAMA Summit Report on Artificial Intelligence)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Artificial intelligence (AI) is changing health and health care on an unprecedented scale. Though the potential benefits are massive, so are the risks. The JAMA Summit on AI discussed how health and health care AI should be developed, evaluated, regulated, disseminated, and monitored.

OBSERVATIONS: Health and health care AI is wide-ranging, including clinical tools (eg, sepsis alerts or diabetic retinopathy screening software), technologies used by individuals with health concerns (eg, mobile health apps), tools used by health care systems to improve business operations (eg, revenue cycle management or scheduling), and hybrid tools supporting both business operations (eg, documentation and billing) and clinical activities (eg, suggesting diagnoses or treatment plans). Many AI tools are already widely adopted, especially for medical imaging, mobile health, health care business operations, and hybrid functions like scribing outpatient visits. All these tools can have important health effects (good or bad), but these effects are often not quantified because evaluations are extremely challenging or not required, in part because many are outside the US Food and Drug Administration's regulatory oversight. A major challenge in evaluation is that a tool's effects are highly dependent on the human-computer interface, user training, and setting in which the tool is used. Numerous efforts lay out standards for the responsible use of AI, but most focus on monitoring for safety (eg, detection of model hallucinations) or institutional compliance with various process measures, and do not address effectiveness (ie, demonstration of improved outcomes). Ensuring AI is deployed equitably and in a manner that improves health outcomes or, if improving efficiency of health care delivery, does so safely, requires progress in 4 areas. First, multistakeholder engagement throughout the total product life cycle is needed. This effort would include greater partnership of end users with developers in initial tool creation and greater partnership of developers, regulators, and health care systems in the evaluation of tools as they are deployed. Second, measurement tools for evaluation and monitoring should be developed and disseminated. Beyond proposed monitoring and certification initiatives, this will require new methods and expertise to allow health care systems to conduct or participate in rapid, efficient, and robust evaluations of effectiveness. The third priority is creation of a nationally representative data infrastructure and learning environment to support the generation of generalizable knowledge about health effects of AI tools across different settings. Fourth, an incentive structure should be promoted, using market forces and policy levers, to drive these changes.

CONCLUSIONS AND RELEVANCE: AI will disrupt every part of health and health care delivery in the coming years. Given the many long-standing problems in health care, this disruption represents an incredible opportunity. However, the odds that this disruption will improve health for all will depend heavily on the creation of an ecosystem capable of rapid, efficient, robust, and generalizable knowledge about the consequences of these tools on health.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Angus DC, Khera R, Lieu T, et al. AI, Health, and Health Care Today and Tomorrow: The JAMA Summit Report on Artificial Intelligence. JAMA. 2025. PMID: 41082366. doi:10.1001/jama.2025.18490

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。